EPM Scientific

Belkins
EPM Scientific exists to enable exceptional careers around the world; we connect exceptional talent, with exceptional opportunities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed | February 15, 2021

news image

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More

PHARMACY MARKET

AIZON LAUNCHES GXP AI BIOREACTOR APPLICATION FOR THE PHARMA INDUSTRY

Aizon | February 02, 2021

news image

Aizon launches its Bioreactor Application, the pharma industry's first predictive analysis and profound knowledge management application. The Aizon Bioreactor Application adds the bioreactor process to the "Smart Manufacturing" transformation that is accelerating across the Pharma and Biotech industry. Aizon is extraordinarily able to achieve GxP compliance and give an audit trail from the start of the process. The turnkey application allows pharmaceutical and biotech companies to ...

Read More

ELI LILLY, SITRYX SIGN POTENTIAL $880M DEAL TO DEVELOP IMMUNOMETABOLIC MEDICINES

Pharmaceutical Business review - | April 01, 2020

news image

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets may help develop potential new medicines for autoimmune diseases. Lilly immunology vice president Dr Ajay Nirula said: “As Lilly seeks to develop new and unique medicines for people s...

Read More

RESEARCH

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

news image

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More

RESEARCH

MindMed | February 15, 2021

news image

MINDMED SIGNS PARTNERSHIP WITH SWISS PSYCHEDELIC DRUG DISCOVERY STARTUP MINDSHIFT COMPOUNDS AG

MindMed, a leading psychedelic medicine biotech company announced another partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties. As a component of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together. The first initial compounds have just been combined by MindShift Compounds AG and related patent applicati...

Read More

PHARMACY MARKET

Aizon | February 02, 2021

news image

AIZON LAUNCHES GXP AI BIOREACTOR APPLICATION FOR THE PHARMA INDUSTRY

Aizon launches its Bioreactor Application, the pharma industry's first predictive analysis and profound knowledge management application. The Aizon Bioreactor Application adds the bioreactor process to the "Smart Manufacturing" transformation that is accelerating across the Pharma and Biotech industry. Aizon is extraordinarily able to achieve GxP compliance and give an audit trail from the start of the process. The turnkey application allows pharmaceutical and biotech companies to ...

Read More

Pharmaceutical Business review - | April 01, 2020

news image

ELI LILLY, SITRYX SIGN POTENTIAL $880M DEAL TO DEVELOP IMMUNOMETABOLIC MEDICINES

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets may help develop potential new medicines for autoimmune diseases. Lilly immunology vice president Dr Ajay Nirula said: “As Lilly seeks to develop new and unique medicines for people s...

Read More

RESEARCH

Eli Lilly | November 11, 2020

news image

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More